<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00808535</url>
  </required_header>
  <id_info>
    <org_study_id>CMRI_Perfusion Study</org_study_id>
    <nct_id>NCT00808535</nct_id>
  </id_info>
  <brief_title>Cardiac Magnetic Resonance Imaging for Detecting Endothelial Dysfunction</brief_title>
  <official_title>A Pilot Study of Cardiac Magnetic Resonance Imaging For Detection of Myocardial Perfusion Abnormalities in Endothelial Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bracco Diagnostics, Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this research study is to demonstrate that Cardiac Perfusion MRI with Vasomotor&#xD;
      Stress may serve as a non-invasive and less risky imaging technique for detecting&#xD;
      non-obstructive perfusion deficits and/or abnormalities in myocardial blood flow (MBF) in&#xD;
      patients with endothelial dysfunction.&#xD;
&#xD;
      This is a controlled study, which will enroll approximately 60 subjects (30 diabetics and 30&#xD;
      non-diabetics to serve as healthy controls), and will include male and non-pregnant females,&#xD;
      between the ages 18-50 years.&#xD;
&#xD;
      All eligible participants will sign an informed consent and will complete a Lifestyle&#xD;
      Questionnaire. They will undergo blood work which includes:&#xD;
&#xD;
        -  2-hour Oral Glucose Tolerance Test and Fasting Labs for Glucose, Insulin, C-Peptide,&#xD;
           HbA1c, Creatinine, and Lipid Panel.&#xD;
&#xD;
        -  Urine Albumin to Creatinine ratio for microalbuminuria.&#xD;
&#xD;
        -  Serum inflammatory markers: E-selectin, homocysteine, ADMA, VCAM, IL-6, TNFalpha, hs-CRP&#xD;
           and PAI-1.&#xD;
&#xD;
      After blood work, all participants will undergo cardiac MR perfusion imaging procedure with&#xD;
      Cold Pressor Test and Adenosine Stress Test.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>February 2009</start_date>
  <completion_date type="Anticipated">March 2010</completion_date>
  <primary_completion_date type="Anticipated">February 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Endothelial Dysfunction</condition>
  <condition>Myocardial Perfusion Abnormalities</condition>
  <condition>Cardiac MRI Perfusion With Vasomotor Stress</condition>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>diabetics</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy controls</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cardiac Perfusion MRI w Vasomotor Stress</intervention_name>
    <description>All participants will undergo Cardiac Perfusion MRI with Vasomotor Stress. Vasomotor Stress will include both Cold Pressor Test and Adenosine Stress Test.</description>
    <arm_group_label>diabetics</arm_group_label>
    <arm_group_label>healthy controls</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Diagnosed diabetics (less than 5 years) without documented coronary artery disease&#xD;
        recruited from UCLA Ambulatory clinics.&#xD;
&#xD;
        Healthy controls from general population.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 to 50 years&#xD;
&#xD;
          -  Should be able to sign an informed consent and HIPAA Agreement&#xD;
&#xD;
          -  30 healthy, non-diabetic individuals&#xD;
&#xD;
          -  30 diabetic individuals without documented coronary artery disease&#xD;
&#xD;
          -  Diagnosed diabetics less than 5 years&#xD;
&#xD;
          -  HbA1c less than 8.0&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Children under 18 years and adults above 50 years&#xD;
&#xD;
          -  Type 1 DM&#xD;
&#xD;
          -  Lactating and Pregnant females&#xD;
&#xD;
          -  BMI less than 35&#xD;
&#xD;
          -  Contraindication to MRI such as pacemaker, defibrillator implants, etc.&#xD;
&#xD;
          -  Allergy to MR (paramagnetic) contrast&#xD;
&#xD;
          -  History of Angina, MI, or documented Coronary Artery Disease&#xD;
&#xD;
          -  Previous history of CHF, CABG, Angioplasty and Stenting&#xD;
&#xD;
          -  History of Valvular Heart Disease and Congenital Heart Disease&#xD;
&#xD;
          -  History of Peripheral Vascular Disease&#xD;
&#xD;
          -  History of Cardiac Arrythmias and anti-coagulation therapy&#xD;
&#xD;
          -  History of Cerebro-vascular accidents or TIA&#xD;
&#xD;
          -  History of active diabetic retinopathy and nephropathy&#xD;
&#xD;
          -  Uncontrolled hypertension (systolic &gt; 170 and diastolic &gt;100 mm Hg&#xD;
&#xD;
          -  End Stage Renal Disease and patients on dialysis&#xD;
&#xD;
          -  HbA1c of 8.0&#xD;
&#xD;
          -  Creatinine greater than 1.7 mg/dl&#xD;
&#xD;
          -  History of active gastrointestinal bleeding&#xD;
&#xD;
          -  History of IV drug use&#xD;
&#xD;
          -  Chronic or current steroid treatment&#xD;
&#xD;
          -  Growth hormone treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Ruehm, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA Radiological Sciences</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>91324</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Wanda C Marfori, MD</last_name>
      <phone>310-206-2531</phone>
      <email>wmarfori@mednet.ucla.edu</email>
    </contact>
    <contact_backup>
      <last_name>Stefan Ruehm, MD</last_name>
      <phone>3108250958</phone>
      <email>sruehm@mednet.ucla.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Stefan Ruehm, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jonathan Goldin, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mayil Krishnam, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christine Darwin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2009</verification_date>
  <study_first_submitted>December 15, 2008</study_first_submitted>
  <study_first_submitted_qc>December 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2008</study_first_posted>
  <last_update_submitted>February 6, 2009</last_update_submitted>
  <last_update_submitted_qc>February 6, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2009</last_update_posted>
  <responsible_party>
    <name_title>Stefan Ruehm, MD</name_title>
    <organization>UCLA</organization>
  </responsible_party>
  <keyword>Endothelial dysfunction</keyword>
  <keyword>Cardiac Perfusion MRI</keyword>
  <keyword>Vasomotor Stress</keyword>
  <keyword>Cold Pressor Test</keyword>
  <keyword>Adenosine Stress</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Congenital Abnormalities</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

